Ivermectin Orifarm

Ivermectin, the active ingredient in Ivermectin Orifarm, is an anthelmintic (macrocyclic lactone) presented as an oral formulation for oral use. It treats parasitic infections such as onchocerciasis, strongyloidiasis, lymphatic filariasis and scabies in appropriate patients.

GNH USA supplies Ivermectin Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivermectin is an antiparasitic agent used to treat infections caused by nematodes and ectoparasites.

Onchocerciasis: reduces microfilarial load and prevents disease progression. Strongyloidiasis: eliminates intestinal larvae and prevents hyperinfection. Lymphatic filariasis: lowers circulating microfilariae, aiding control programs. Scabies: eradicates Sarcoptes scabiei mites, relieving skin symptoms.

Ivermectin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Dizziness: transient light‑headedness. - Pruritus: skin itching at sites of parasite death.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Neurological events: seizures, encephalopathy, or ataxia. - Hepatotoxicity: elevated liver enzymes or hepatitis.

When prescribing Ivermectin, clinicians should consider several safety aspects. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: limited data; weigh potential infant exposure against maternal benefit. - Renal impairment: use with caution; monitor if possible. - Strong CYP3A4 inhibitors: may increase exposure; adjust therapy as needed. - Drug interactions: review concomitant medications for additive toxicity. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Ivermectin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivermectin plasma concentrations. - P‑glycoprotein inhibitors (e.g., verapamil): can raise systemic exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Anticonvulsants (e.g., carbamazepine): may reduce ivermectin levels. - Other antiparasitics (e.g., albendazole): potential additive toxicity; assess clinical need.